Onconic Therapeutics Inc. (KOSDAQ:476060)

South Korea flag South Korea · Delayed Price · Currency is KRW
23,950
-1,150 (-4.58%)
At close: Mar 20, 2026
Market Cap1.08T +547.0%
Revenue (ttm)53.39B +259.8%
Net Income15.78B
EPSn/a
Shares Out44.89M
PE Ratio68.11
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume605,942
Average Volume2,003,579
Open25,000
Previous Close25,100
Day's Range23,850 - 25,100
52-Week Range3,878 - 28,900
Betan/a
RSI56.30
Earnings DateMar 20, 2026

About Onconic Therapeutics

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Kor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 476060
Full Company Profile

Financial Performance

Financial Statements